GlassScriptPhysician profile
Scott M Agnew
NPI 1306876628
$11,014.20
in general payments reported to CMS, 2019-2025
51 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,384 · 2020: $1,231 · 2021: $1,719 · 2022: $1,853 · 2023: $2,433 · 2024: $2,104 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,827.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,164.06 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $984.34 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $797.95 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $735.99 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $719.53 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $698.22 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Amarin Pharma, INC. | $598.95 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $555.28 | 2019-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $493.32 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $385.23 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $357.39 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $352.94 | 2019-2023 | Verquvo, Dificid, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $343.51 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $315.29 | 2019-2023 | |
| Abbott Laboratories | $311.11 | 2021-2025 | Freestyle Libre 3 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Agnew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.